A trilateral agreement between GENERIUM, the leader of Russian biotechnology, BIOSUN PHARMED, an Iranian company, and RSC Pharm, a Russian company, was signed on February 7 in the Iranian Embassy in Moscow.
The parties agreed on strategic collaboration in the exports of Russian biotech drugs manufactured by GENERIUM for TB diagnosis and treatment of rare diseases, as well as on the gradual transfer of technology for their manufacturing in the Islamic Republic of Iran.
The agreement is the result of implementing the GENERIUM’s strategy to develop its export capacity. The drugs of the company for the treatment of hemophilia and TB diagnosis are in the process of registration in Latin America, Middle East, and Southeast Asia. The pilot supplies were delivered to Bangladesh and Mauritius. In addition to CIS and Iran, the exports are planned to Lebanon and Vietnam.
“Today’s event is important in terms of cutting the budget costs for TB diagnosis and reducing mortality rates for the Iranian side and expanding the export capacity for the Russian side. We have visited Tehran several times, got acquainted with the national culture; in Iran, people appreciate the value of money, but they value human relationships even more. With this approach, our partnership is destined to succeed,” said Professor Dmitry Kudlay, the General Director of GENERIUM JSC.